Integrative clinical transcriptomics analyses for new therapeutic intervention strategies: a psoriasis case study

•Disease and drug MOA understanding is critical for new therapeutic discovery.•Clinical transcriptomics from psoriasis is of great value for psoriasis research.•Integrative analysis can provide a framework for efficient hypothesis generation.•Target identification and drug repositioning are important drug development strategy.•Framework presented here is amenable for open therapeutic innovation in psoriasis. Psoriasis is a chronic inflammatory skin disease with complex pathological features and unmet pharmacotherapy needs. Here, we present a framework for developing new therapeutic intervention strategies for psoriasis by utilizing publicly available clinical transcriptomics data sets. By exploring the underlying molecular mechanisms of psoriasis, the effects of subsequent perturbation of these mechanisms by drugs and an integrative analysis, we propose a psoriasis disease signature, identify potential drug repurposing opportunities and present novel target selection methodologies. We anticipate that the outlined methodology or similar approaches will further support biomarker discovery and the development of new drugs for psoriasis.